Aemetis (NASDAQ:AMTX) Price Target Lowered to $20.00 at Ascendiant Capital Markets

Aemetis (NASDAQ:AMTX) had its price target decreased by equities researchers at Ascendiant Capital Markets from $21.00 to $20.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the specialty chemicals company’s stock.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aemetis in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Aemetis currently has a consensus rating of “Moderate Buy” and an average target price of $17.00.

Aemetis Stock Performance

Aemetis stock opened at $1.76 on Wednesday. Aemetis has a 52 week low of $1.22 and a 52 week high of $4.32. The stock has a market capitalization of $115.40 million, a P/E ratio of -1.09 and a beta of 1.73. The stock has a fifty day moving average of $2.39 and a 200-day moving average of $2.36.

Aemetis (NASDAQ:AMTX) last released its earnings results on Friday, November 7th. The specialty chemicals company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.12). The business had revenue of $59.19 million during the quarter, compared to analysts’ expectations of $87.79 million. On average, research analysts forecast that Aemetis will post -2.07 earnings per share for the current year.

Hedge Funds Weigh In On Aemetis

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in shares of Aemetis by 15.3% during the third quarter. Vanguard Group Inc. now owns 2,479,163 shares of the specialty chemicals company’s stock worth $5,578,000 after purchasing an additional 329,760 shares during the period. Jane Street Group LLC acquired a new position in Aemetis during the 2nd quarter worth about $634,000. Goldman Sachs Group Inc. lifted its holdings in Aemetis by 71.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 218,404 shares of the specialty chemicals company’s stock worth $380,000 after buying an additional 91,367 shares during the period. GSA Capital Partners LLP grew its position in shares of Aemetis by 42.4% in the 3rd quarter. GSA Capital Partners LLP now owns 179,790 shares of the specialty chemicals company’s stock valued at $405,000 after buying an additional 53,508 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its stake in shares of Aemetis by 14.2% in the first quarter. PNC Financial Services Group Inc. now owns 113,560 shares of the specialty chemicals company’s stock valued at $198,000 after buying an additional 14,152 shares during the period. 27.02% of the stock is currently owned by institutional investors and hedge funds.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.